Research programme: cancer therapeutics - Exotech Bio/ Precigen Inc
Latest Information Update: 28 May 2020
At a glance
- Originator Exotech Bio
- Developer Precigen Inc
- Class Exosome therapies; Gene therapies; RNA
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2020 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 03 Feb 2020 Intrexon Corporation is now called Precigen Inc
- 13 Apr 2016 Early research in Cancer in USA (Parenteral)